Scientists at the Belgian biotech company etherna are exploring new approaches to address autoimmune diseases, which have traditionally been treated with immune-suppressing medications, such as corticosteroids and anti-cytokine antibodies. While these treatments can alleviate symptoms, they can also increase susceptibility to infections and cancer over time, highlighting the need for more effective therapies.
Data from the U.S. National Health Council indicates a rising trend in autoimmune diseases, prompting interest in innovative treatment options. Various emerging technologies are being developed to improve patient outcomes.
One approach is CAR T-cell therapy, primarily used in cancer treatment, which has shown promise in targeting autoreactive B cells linked to autoimmune diseases. A German study reported that CAR T-cell therapy successfully induced remission in lupus patients by eliminating these problematic cells. However, scaling this therapy for wider use remains a challenge.
Another avenue is the development of immune engager molecules by Coding Bio, which aim to facilitate the targeted destruction of autoreactive B cells in a more accessible manner.
Nuvig Therapeutics is working on a novel drug, NVG-2089, designed to enhance the anti-inflammatory effects of immunoglobulin G (IgG) autoantibodies. This drug, which has shown increased potency in preclinical trials, is expected to simplify treatment administration compared to traditional intravenous immunoglobulin therapy.
Additionally, etherna is investigating inverse RNA vaccines that may train the immune system to disregard harmful autoantigens, potentially leading to long-term therapeutic effects for conditions like multiple sclerosis.
Lastly, Hansa Biopharma is pioneering enzyme-based treatments to degrade pathogenic antibodies linked to autoimmune diseases. Their ongoing clinical trials aim to provide more rapid and effective treatment options.
These developments signal a potential shift in the treatment landscape for autoimmune diseases, offering hope for improved patient care.